Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam receives $20 million milestone from Takeda

This article was originally published in Scrip

Executive Summary

Alnylam Pharmaceuticals has received a milestone payment of $20 million from Takedaas part of the companies' May alliance for RNA interference therapeutics. The sum was for the transfer of selected technology, materials and know-how under the potential $1 billion-plus global tie-up, which could see the US firm receive a further $30 million in near-term milestones. The collaboration is focusing on oncology and metabolic disease initially and also involves the cross licensing of delivery technologies and a joint discovery programme. Alnylam has an option to co-develop and co-commercialise in the US any Takeda RNAi therapeutics emerging from the agreement (Scrip Online, May27th, 2008).

You may also be interested in...



Dissecting The Impact: Chi-Med Details Coronavirus Experience

CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical. 

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.

Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access

A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context

Topics

Related Companies

UsernamePublicRestriction

Register

SC029171

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel